

Review of: "Tocilizumab Plus Corticosteroid in Elderly Patients Hospitalized With COVID-19 Pneumonia: A Retrospective Cohort Study"

Rafael Resende¹

¹ Fundação Oswaldo Cruz

Potential competing interests: No potential competing interests to declare.

The study is relevant although some minor modifications must be addressed.

Abstract: 1) Number of patients should be described in Methods. 2) The role of Tocilizumab as an IL-6 inhibitor should be described.

Methods: It is expected that most of the patients were previously vaccinated for COVID-19. If the authors have a vaccination log (including vaccine type/brand, number of doses, and side effects) of the patients, this must be considered, otherwise, it should be mentioned in the Discussion.